Abstract | OBJECTIVES: DESIGN: Decision-analytic model to estimate lifetime costs, life-expectancy, and quality-adjusted life years (QALYs) with ticagrelor and clopidogrel. Event rates, healthcare resource use, and health-related quality of life during 12 months of therapy were estimated from the PLATelet inhibition and patient Outcomes (PLATO) trial. Beyond 12 months, quality-adjusted survival and costs were estimated conditional on events occurring during the 12 months of therapy. When available, country-specific data were employed in the analysis. Incremental cost-effectiveness ratios are presented from a healthcare perspective and a broader societal perspective including costs falling outside the healthcare sector in 2010 local currency. RESULTS: The cost per QALY with ticagrelor compared with generic clopidogrel was SEK 25 022 and DKK 26 892 for Sweden and Denmark, respectively, from a healthcare perspective. The cost per QALY from a broader societal perspective was SEK 24 290 and DKK 25 051 for Sweden and Denmark, respectively. CONCLUSION: The cost per QALY of treating ACS-patients with ticagrelor compared with generic clopidogrel is below the conventional thresholds of cost-effectiveness in Sweden and Denmark.
|
Authors | Martin Henriksson, Elisabet Nikolic, Audun Ohna, Lars Wallentin, Magnus Janzon |
Journal | Scandinavian cardiovascular journal : SCJ
(Scand Cardiovasc J)
Vol. 48
Issue 3
Pg. 138-47
(Jun 2014)
ISSN: 1651-2006 [Electronic] England |
PMID | 24650118
(Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Purinergic P2Y Receptor Antagonists
- Clopidogrel
- Ticagrelor
- Adenosine
- Ticlopidine
|
Topics |
- Acute Coronary Syndrome
(drug therapy)
- Adenosine
(analogs & derivatives, economics, therapeutic use)
- Clopidogrel
- Cost-Benefit Analysis
- Denmark
- Humans
- Purinergic P2Y Receptor Antagonists
(economics, therapeutic use)
- Sweden
- Ticagrelor
- Ticlopidine
(analogs & derivatives, economics, therapeutic use)
|